GlassScriptPhysician profile
Everett H Allen
NPI 1609846641
$25,909.83
in general payments reported to CMS, 2019-2025
49 companies · $6,121 in 2025
The $6,121 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,200 · 2020: $2,059 · 2021: $2,651 · 2022: $3,331 · 2023: $3,906 · 2024: $3,643 · 2025: $6,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,383 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,988.96 |
| Consulting Fee | $1,382.50 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,210.58 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Ucb, INC. | $1,994.78 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,969.81 | 2019-2025 | Tremfya, Simponi Aria, Acclarent Aera |
| Novartis Pharmaceuticals Corporation | $1,916.79 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,570.05 | 2020-2025 | Acthar |
| Invivyd INC | $1,441.40 | 2025 | Pemgarda |
| Glaxosmithkline, LLC. | $1,385.98 | 2019-2025 | Benlysta, Arexvy, Nucala |
| E.R. Squibb & Sons, L.L.C. | $1,320.68 | 2019-2025 | Orencia, Cobenfy |
| Horizon Therapeutics Plc | $1,278.04 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $1,158.74 | 2019-2024 | Taltz |
| Pfizer INC. | $960.37 | 2019-2025 | |
| Pacira Therapeutics, INC. | $640.01 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $618.16 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $615.91 | 2019-2025 | Tymlos |
| Abbvie INC. | $533.38 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everett Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.